INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTA..
ISTH 2026 Congress11 - 15 July Paris
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| 1005-PB | Outcomes of Anemic versus Non-Anemic Patients Anticoagulated for Atrial Fibrillation and/or Venous Thromboembolic Disease | Jordan Schaefer |  Received |
 |
|||
| 1018-PB | Derivation and Validation of Natural Language Processing for the Detection of Ischemic Stroke in Electronic Health Records | Kayan Irani | Received |
|
|||
| 1049-PB | Relation between Lipoprotein(a), Oxidized Phospholipids and Platelet-fibrin Clot Strength in Cardiovascular Disease Patients Undergoing Percutaneous Intervention | Udaya Tantry | Received |
|
|||
| 1066-PB | Cardiac troponin I and NT-proBNP as the predictors of cardiovascular outcome in Thai patients undergoing hip surgery : A prospective observational study | Pitiphong Kijrattanakul | Received |
|
|||
| 1068-PB | In vitro hemostatic and fibrinolytic parameters and their association with coronary blood flow and clinical outcomes in acute myocardial infarction | Anna Kalinskaya | Received |
|
|||
| 1075-PB | Blood group O is associated with reduced intraluminal thrombus burden in abdominal aortic aneurysms | Alison Michels | Received |
|
|||
| 1076-PB | Soluble CD146 Reflects Altered Endothelial and Metabolic Homeostasis in Peripheral Artery Disease | Haizam Oubari | Received |
|
|||
| 1080-PB | Lipoprotein(a) Levels in Patients with Peripheral Arterial Disease Undergoing Endovascular Intervention: A Post-hoc Analysis of the SirPAD trial | Rimann Leonie | Received |
|
|||
| 1087-PB | Switch from plasma to recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura: the French experience. | Berangere Joly | Received |
|
|||
| 1088-PB | Characterization of the anti-ADAMTS13 immune response in non-idiopathic immune-mediated thrombotic thrombocytopenic purpura. | Berangere JOLY | Received |
|
|||
| 1094-PB | Evaluation of a Sysmex Rapid Automated ADAMTS13 Activity Assay | Thomas Pitchford | Received |
|
|||
| 1103-PB | Thrombotic Thrombocytopenic Purpura in Singapore (2017–2024): National Incidence and Anti-ADAMTS13 Autoantibodies | TONG TONG | Received |
|
|||
| 1106-PB | Site-specific citrullination of ADAMTS13 reveals impact of arginine deimination on activity | Jan Voorberg | Received |
|
|||
| 1109-PB | The Von Willebrand factor/ADAMTS13 axis is persistently impaired in sepsis. | Joshua Muia | Received |
|
|||
| 1117-PB | The Contribution of Rare Coding Variation in Antithrombin (SERPINC1) to Thrombosis Risk in a Population-scale Analysis | Justine Ryu | Received |
|
|||
| 1129-PB | Outcomes Associated With Treatment Strategies for Heparin Resistance in a Large Retrospective Cohort | Simon Bakhos Bechara | Received |
|
|||
| 1148-PB | Elucidating the role of Tandem C2 domain nuclear protein in VWF Biosynthesis via knockdown and knockout models | Colleen Notley | Received |
|
|||
| 1152-PB | von Willebrand Factor fibers formed at pathological high shear provide a scaffold for α-synuclein binding and aggregation | Jason Rossi | Received |
|
|||
| 1154-PB | Detection of Anti-VWF Antibodies in Patients with Acquired von Willebrand Disease: Case Studies | Tina Agostini | Received |
|
|||
| 1158-PB | Laboratory Phenotype of Acquired Von Willebrand Syndrome in Polycythemia Vera and Essential Thrombocythemia | Mohamed Hussam Aswad | Received |
|
|||
| 1160-PB | MGP knockdown decreases endothelial VWF expression | Christopher Ng | Received |
|
|||
| 1163-PB | Investigating the Effect of Population Pharmacokinetic-Guided pdVWF/FVIII (1:1) Prophylaxis for Severe VWD in a Real-World Setting: The PopPK-WILPROPHY Study | Ron Mathot | Received |
|
|||
| 1181-PB | Emicizumab use in acquired Von Willebrand Syndrome (aVWS) | Magdalena Lewandowska | Received |
|
|||
| 1202-PB | An Automated Whole-Blood Flow Microfluidic Assay for Integrated Quantification of Platelet Aggregation, Fibrin(ogen) Formation, and Total Thrombus Kinetics in Clinical Hemostasis | Alessandro Foladore | Received |
|
|||
| 1210-PB | Standardization of HIT Diagnostic Assays, with K070, a chimeric human-mouse antibody, mimicking heparin dependent pathogenic antibodies | Nicolas Bouveyron | Received |
|
|||
| 1220-PB | Performance characteristics of Antithrombin laboratory assays in the low range concentrations and between assay consistence | Claire Dunois | Received |
|
|||
| 1221-PB | Multicenter prospective evaluation of MRX PT-DOAC for identifying clinically relevant direct oral anticoagulant (DOAC) drug levels | Siraj Mithoowani | Received |
|
|||
| 1223-PB | Assessment of the Enhanced HIL Function on the Sysmex CN™-700 Automated Blood Coagulation Analyser: Precision Evaluation and Comparative Analysis with the Sysmex CN™-6000 Automated Blood Coagulation Analyser | Kevin Horner | Received |
|
|||
| 1226-PB | Consistent discrepancies between INRs determined with different reagents; Data from UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation | Steve Kitchen | Received |
|
|||
| 1235-PB | Feasibility of cangrelor-spiked specimens for platelet function proficiency testing across three survey formats | Eric Salazar | Received |
|
|||
| 1237-PB | Accuracy and Precision of Extrinsic Pathway Assays – data from UK NEQAS (Blood Coagulation). Proficiency Testing results with the ISTH/SSC Plasma Standard | Ian Jennings | Received |
|
|||
| 1239-PB | Viscoelastic testing in Patient Blood Management: FIBTEM C A5 equivalence across ROTEM® sigma cartridge configurations. | Tanya Feguson | Received |
|
|||
| 1242-PB | Performance evaluation of the novel HISCL™ HIT IgG assay kit | Brigitte Tardy | Received |
|
|||
| 1250-PB | Precision and Reproducibility of New Automated Chemiluminescent Immunoassays (CLIA) for the Detection of Antiphospholipid IgG Antibodies | Pablo Martínez-Valera | Received |
|
|||
| 1252-PB | Interferences in New Automated Chemiluminescent Immunoassays (CLIA) for Antiphospholipid IgG Antibodies Detection | Pablo Martínez-Valera | Received |
|
|||
| 1253-PB | An Automated Lupus Anticoagulant Assay Resistant to Anticoagulant Drugs including DOACs and Oral FXI Inhibitors | Elaine Benoit | Received |
|
|||
| 1257-PB | Compound heterozygous ITGB3 variants in an infant with bleeding consistent with a Glanzmann thrombasthenia phenotype | Eric Salazar | Received |
|
|||
| 1258-PB | Prothrombin protein levels in patients with IgG anti phosphstidyl-serine/prothrombin antibodies | Vittorio Pengo | Received |
|
|||
| 1265-PB | Interferences in New Automated Chemiluminescent Immunoassays for Antiphospholipid IgM Antibodies Detection | Niki Leonard | Received |
|
|||
| 1267-PB | Clinical Validation of a Point-of-Care Whole Blood Coagulometer in Patients on Factor Xa Inhibitors | Melissa Hammond | Received |
|
|||
| 1268-PB | ComboClot™: A Combined Global Assay of Coagulative and Fibrinolytic Capacity to Simultaneously Measure Thrombin Generation, Plasmin Generation, and Clot Formation and Lysis | Steven Bruzek | Received |
|
|||
| 1270-PB | Validation of a Pre-Calibration Strategy for Prothrombin Time (PT) Testing: Assessing Instrument Harmonization and Analytical Accuracy | Maya Schamroth Rossade | Received |
|
|||
| 1277-PB | Precision and Reproducibility of New Automated Chemiluminescent Immunoassays (CLIA) for the Detection of Antiphospholipid IgM Antibodies | Niki Leonard | Received |
|
|||
| 1288-PB | Favorable Precision, Evaluation, and Correlation Data Supporting Regulatory Submission of a Novel Automated Coagulation Analyzer | Paul Riley | Received |
|
|||
| 1290-PB | Unexplained D-Dimer Elevation: The Importance of Methodological Cross Check | kieron hickey | Received |
|
|||
| 1297-PB | Intramolecular crosslinked and stabilized thrombin for long-term stable liquid Fibrinogen and Thrombin Time reagentsIntramolecular crosslinked and stabilized thrombin for long-term stable liquid Fibrinogen and Thrombin Time reagents. | Jean Amiral | Received |
|
|||
| 1301-PB | Healthy Adults Demonstrate Narrower Variability for Thrombelastography Parameters Compared with Manufacturer Reference Ranges | Prism Schneider | Received |
|
|||
| 1303-PB | Evaluation of the New Sysmex CN™-700 Automated Blood Coagulation Analyser: Precision Data and Method Comparison with the Sysmex CN™-6000. | Kevin Horner | Received |
|
|||
| 1305-PB | Performance of new platform for coagulation automated assays | Claire Dunois | Received |
|
|||
| 1310-PB | Comparative Method and Efficiency Assessment Of The New Sysmex CN™-700 Automated Blood Coagulation Analyser With The Sysmex CA-660 Automated Blood Coagulation Analyser. | Kerensa Leeson | Received |
|
|||
| 1316-PB | Assessment of aspirin response in neuroendovascular patients: comparison of five platelet function tests across light transmission aggregometry and a cartridge-based assay | Tasuku Sakayori | Received |
|
|||
| 1324-PB | Investigating the Impact of Monoclonal Gammopathy (MGUS) on Prothrombin Time and Thrombin Time (TT) Coagulation Assays: A Method Comparison Study | Maya Schamroth Rossade | Received |
|
|||
| 1329-PB | Metabolic changes associated with acute pulmonary embolism and supplemental oxygen: a prospective, experimental, controlled study | Christopher Kabrhel | Received |
|
|||
| 1339-PB | Role of Tissue Transglutaminase 2 in Fibrin Formation and Haemostasis | Verena Schröder | Received |
|
|||
| 1343-PB | Development of a rapid test (lateral flow assay) for coagulation factor XIII | Verena Schroeder | Received |
|
|||
| 1345-PB | Factor XIII deficiency in children in RUSSIA | Dmitry Florinskiy | Received |
|
|||
| 1346-PB | Discrepancy between factor XIII activity and severe bleeding phenotype in two Caucasian siblings with umbilical stamp bleeding – when to assess factor XIII antigens? | Julia Radon-Proskura | Received |
|
|||
| 1350-PB | Functional role of the interaction between fibrin and the endothelial cell receptor N-cadherin | Leonid Medved | Received |
|
|||
| 1360-PB | Is N-cadherin a novel endothelial cell receptor for the fibrin-derived ß15-42 fragment? | Sergiy Yakovlev | Received |
|
|||
| 1361-PB | Increased Number of Crosslinking Sites for Factor XIII Overrules the Mechanical and Lytic Destabilization of Fibrin Caused by Citrullination of Fibrinogen | Anna Tanka-Salamon | Received |
|
|||
| 1368-PB | Interpretation of Genetic Variants in Congenital Fibrinogen Disorders with Diverse Phenotypes | Keiko Shinozawa | Received |
|
|||
| 1383-PB | Case report: Management of severe hypodysfibrinogenemia in multiple high risk pregnancies in a tertiary haemophilia centre | Rebecca Walsh | Received |
|
|||
| 1385-PB | Hypodysfibrinogenemia in a young woman: A case report | Sachini Gunasiri | Received |
|
|||
| 1386-PB | Fibrinolytic Dysregulation in Osteoarthritis: Clinical Associations with Plasminogen Activator Pathways | Iryna Korzh | Received |
|
|||
| 1389-PB | Alpha2-Antiplasmin Causes Endothelial Damage, Blood Brain Barrier Breakdown, Neuroinflammation and Disability in Ischemic Stroke Without Reperfusion | Guy Reed | Received |
|
|||
| 1390-PB | The Yersinia pestis plasminogen activating virulence factor, Pla, identifies black rats over other rodents as a significant host for plague transmission to humans. | Jeffrey Weitz | Received |
|
|||
| 1395-PB | A novel thrombomodulin (TM)/TAFI functional assay revealed that impaired TM and TAFI functions triggered severe bleeding in both congenital TM abnormality and acute promyelocytic leukemia. | Tetsumei Urano | Received |
|
|||
| 1403-PB | Association of Fibrinogen Levels and Changes in Fibrinogen with VTE After Injury | Emily Mosher | Received |
|
|||
| 1421-PB | An observational study of the association between tranexamic acid dose and inhibition of tissue plasminogen activated stimulated ex vivo fibrinolysis assessed by rotational thromboelastometry in cardiac surgery patients | Gerhardus Kuiper | Received |
|
|||
| 1425-PB | Comparison of fibrinolysis factors and lysis kinetics on normal plasmas and their corresponding euglobulin fractions | Jean Amiral | Received |
|
|||
| 1431-PB | The societal and environmental impact of Emicizumab: An analysis of dual distribution and dispensing pathways for hemophilia care in France | Quentin Berkovitch | Received |
|
|||
| 1441-PB | Real-World Indirect Cost Burden and Patient-Reported Outcomes in Adults with Hemophilia A in the United States — A CHESS-US Analysis | Emily Waters | Received |
|
|||
| 1450-PB | Comorbidities and Mortality in the Aging Hemophilia Population, A Large Real-World Analysis | Stacey Fedewa | Received |
|
|||
| 1451-PB | Immune Tolerance Induction in Haemophilia A Patients with Inhibitors: Updated Analysis from MOTIVATE | Holly Maydew | Received |
|
|||
| 1467-PB | Maternal FVIII Can Be the First FVIII Exposure in Neonates with Severe Hemophilia A | Kerry Lannert | Received |
|
|||
| 1479-PB | Optimization of pre analytical heat treatment in samples containing Extended or Ultra-Long Half-Life Factor VIII concentrate | Anne Riddell | Received |
|
|||
| 1481-PB | Women and girls with haemophilia: Australian registration rates in an international context | Elise Flynn | Received |
|
|||
| 1486-PB | Age-Stratified Outcomes of Intracranial Hemorrhage in Hemophilia: Insights from a 66-Event Cohort | AKSHAY MIDDINTI | Received |
|
|||
| 1493-PB | COGNITIVE, ADAPTIVE ABILITIES AND BEHAVIORAL SYMPTOMS IN CHILDREN AND ADOLESCENTS WITH HEMOPHILIA: A PILOT STUDY | Roberta Vallone | Received |
|
|||
| 1496-PB | Single Center Chart Review of Hemophilia A Patients with Prior Inhibitors Treated with Recombinant Factor VIII Efanesoctocog Alfa to Assess Inhibitor Recurrence | Ashley Wehrle | Received |
|
|||
| 1497-PB | Real-world effectiveness of emicizumab prophylaxis in severe hemophilia A: Galician Multicenter Clinical Experience | María Rebeca Guzmán Fernández | Received |
|
|||
| 1511-PB | Internet Use Disorder in Patients with Hemophilia: A Cross-Sectional Study | roma vishwanathan | Received |
|
|||
| 1512-PB | Utility of a Brief Checklist for Screening Bleeding Symptoms and Psychological Status in Mothers of Children with Hemophilia | Aya Nakao | Received |
|
|||
| 1531-PB | Discovery of novel anti-PF4 clonotypes in ELISA negative VITT expands the spectrum of pathogenic PF4 antibodies | Vera Ripoll | Received |
|
|||
| 1557-PB | Effects of gamgertamig (OM336), a B cell maturation antigen (BCMA) x CD3 T cell engager antibody, in a patient with active antiphospholipid syndrome and concurrent autoimmune thrombocytopenia | Charlie Zhou | Received |
|
|||
| 1558-PB | CHARACTERIZATION OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN SPAIN. PRELIMINARY RESULTS FROM RESTI: SPANISH REGISTRY OF PRIMARY IMMUNE THROMBOCYTOPENIA | CRISTINA PASCUAL IZQUIERDO | Received |
|
|||
| 1564-PB | Biphasic clinical course of pediatric cytomegalovirus-associated immune thrombocytopenia: early poor treatment response but favorable long-term outcomes | Oded Gilad | Received |
|
|||
| 1565-PB | UK NEQAS Blood Coagulation scheme for the detection Anti-PF4 Antibodies in HIT highlights the limitation of a Latex immunoassay. | Christopher Reilly-Stitt | Received |
|
|||
| 1568-PB | Phenotyping of platelets from adult immune thrombocytopenia (ITP) patients before and after first-line treatment | Bianca Clerici | Received |
|
|||
| 1569-PB | EMPATHI Study: Real-World Evidence on Adult ITP Management, Treatment Response, and Patient Burden in Spain | Estefanía Anguita Espinosa | Received |
|
|||
| 1585-PB | Immune Thrombocytopenia: Real-World Experience From Los Angeles County Safety-Net Hospitals | Sarah Tomassetti | Received |
|
|||
| 1586-PB | Single centre experience with frontline mycophenolate plus prednisolone in newly diagnosed ITP | Phil Choi | Received |
|
|||
| 1588-PB | Sex and age modify climate-related risk of immune thrombocytopenia presentations | Philip Choi | Received |
|
|||
| 1590-PB | UPDATED QUALITY OF LIFE AND DEMOGRAPHICS OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP): DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY | Caroline Kruse | Received |
|
|||
| 1592-PB | Thrombopoietin Receptor Agonists in Immune Thrombocytopenia Associated with Systemic Lupus Erythematosus and Antiphospholipid Syndrome: Efficacy and Thrombotic Safety Concerns | Ali M. Assiri | Received |
|
|||
| 1594-PB | Real-world efficacy and safety of FcRn inhibitor, efgartigimod in relapsed/refractory immune thrombocytopenia: a single-center retrospective study in Japan | Masaki Iino | Received |
|
|||
| 1606-PB | Headache in a patient with ITP treated with avatrombopag: experience from a clinical case | Minerva Montalvo Saavedra | Received |
|
|||
| 1608-PB | Use of avatrombopag in chronic ITP with associated hereditary thrombophilia: experience from a clinical case | Minerva Montalvo Saavedra | Received |
|
|||
| 1612-PB | Venous Thromboembolism Risk After CAR-T Therapy Compared with Autologous Stem Cell Transplantation: A Propensity-Matched Real-World Analysis | Sujan Niraula | Received |
|
|||
| 1613-PB | Timing and clinical course of bleeding events during extended apixaban therapy for cancer-associated thrombosis: Insights from the API-CAT prospective randomised doule-blind trial | Isabelle MAHE | Received |
|
|||
| 1623-PB | Cost-Saving Potential of Targeted NOAC Prophylaxis in High-Risk Multiple Myeloma: A SAVED Score-Based Cost-Utility Analysis from a Canadian Community Cancer Centre Perspective | Anthony Naassan | Received |
|
|||
| 1626-PB | Cancer associated thrombosis in patients with uterine cancer: defining risk factors and impact on survival. | Anjlee Mahajan | Received |
|
|||
| 1630-PB | Incidence of thrombosis and bleeding in patients with JAK2 V617F - positive myeloproliferative neoplasms receiving low-dose aspirin – a systematic review and meta-analysis | Kristina Vrotniakaite-Bajerciene | Received |
|
|||
| 1633-PB | Time dependent risks of recurrent thrombosis and bleeding after catheter-related upper extremity deep vein thrombosis in patients with cancer | Ria Singla | Received |
|
|||
| 1634-PB | Enoxaparin versus Placebo to Prevent Symptomatic Venous Thromboembolism in Hospitalized Adult Medical Patients with Active Cancer: A Subgroup Analysis from the SYMPTOMS Trial | Laura Girardi | Received |
|
|||
| 1635-PB | Delay in Anticoagulant Therapy Initiation and Mortality in Patients with Cancer-Associated Thrombosis | Kelsey Bria | Received |
|
|||
| 1642-PB | CAPE Home: Early management and short-term outcomes of pulmonary embolism in people with and without cancer: a retrospective chart review | Alejandro Godoy | Received |
|
|||
| 1643-PB | Tissue Factor and Microparticle-TF (MP-TF) levels as potential biomarkers of thrombosis in localized and locally advanced prostate cancer | Panagiota Tsiatsiou | Received |
|
|||
| 1646-PB | Psychological Impact of Cancer-Associated Thrombosis: Dual burden and Implications for Quality of Life and Integrated Patient-Centered Care | vandreden patrick | Received |
|
|||
| 1653-PB | Thromboembolic events during perioperative therapy for resectable and borderline resectable pancreatic cancer in the PREOPANC-2 trial | Ruth Anne Laura Willems | Received |
|
|||
| 1661-PB | Prophylactic anticoagulation versus no anticoagulation in patients with isolated tumor thrombus; the retrospective TOTO study | Loula Papageorgiou | Received |
|
|||
| 1666-PB | Comorbidity Burden of Cancer Patients Is Associated With Causes of Death Including Thrombo-Hemostatic Causes in a Single Center Study | Kristen Sanfilippo | Received |
|
|||
| 1669-PB | Efficacy and safety of primary thromboprophylaxis in adult ambulatory cancer patients: A Scholarly Review | Rachel Dillon | Received |
|
|||
| 1674-PB | Long Term Risk of Recurrent Venous Thromboembolism in Adult Patients with Active Cancer and First Catheter-Related Upper Extremity Deep Vein Thrombosis After Discontinuation of Anticoagulant Treatments and Line Removal: A Retrospective Multi-Center Cohort Study – Cancer-CRT Study | Laura Girardi | Received |
|
|||
| 1685-PB | Low follow-up venographic patency yet favorable symptom recovery after primary UEDVT: a real-world cohort | Alejandro Godoy | Received |
|
|||
| 1696-PB | Defining Hypercoagulability in Patients with Surgically-Managed Diaphyseal Tibia Fractures: A Pilot Study | Kayla Viaje | Received |
|
|||
| 1700-PB | Lifetime Cost-effectiveness of Mechanical Thrombectomy Versus Anticoagulation Alone for Acute DVT in the United Kingdom: An Updated Analysis Incorporating 2-year Post-thrombotic Syndrome Rates | Jarrod Collins | Received |
|
|||
| 1709-PB | Soluble Fibrin Reflects Active Thrombogenesis and Distinguishes Pulmonary Embolism Presence and Resolution in Patients with Deep Vein Thrombosis | Noritaka Yada | Received |
|
|||
| 1713-PB | An Evaluation of the TRiP Cast Score for Post-operative Thromboprophylaxis Recommendations for Patients with Tibia and Ankle Fractures | Prism Schneider | Received |
|
|||
| 1717-PB | Antiphospholipid Syndrome (APS): Clinical and Immunoserological Differences Between Primary and Secondary APS in Patients at Hospital Nacional Guillermo Almenara Irigoyen – EsSalud. 2016–2025 | Haydee Iparraguirre | Received |
|
|||
| 1722-PB | The Impact of Social Determinants of Health on the Management of Venous Thromboembolic Disease: A Survey of United States Physicians | Suman Sood | Received |
|
|||
| 1723-PB | Comparative Early Outcomes After Venous Thromboembolism Among Hispanic and Non-Hispanic Patients in the RIETE Registry | Alfonso Tafur | Received |
|
|||
| 1728-PB | In the absence of national guidelines; a single centre experience in the management of Superficial Vein Thrombosis. | Sarah Mohamed | Received |
|
|||
| 1732-PB | Serial Thrombelastography and Platelet Mapping Analysis Can Measure Differences in Platelet and Fibrinogen Contribution to Coagulopathy Based on Fracture Type | Kayla Viaje | Received |
|
|||
| 1740-PB | Venous thromboembolism trends in Singapore: A comparative analysis with Rest of Asia- Garfield VTE Registry. | farooq akram | Received |
|
|||
| 1741-PB | Cost-Effectiveness of Extended Apixaban Treatment for Provoked Venous Thromboembolism | Kevin Zablonski | Received |
|
|||
| 1746-PB | Age-adjusted D-dimer for the diagnosis of deep vein thrombosis in patients with cancer: A single-center retrospective study | Tatsuya Konishi | Received |
|
|||
| 1750-PB | Platelet Mapping Analysis Can Measure Post-Operative Antiplatelet Activity Following Femur Fracture Fixation | Kayla Viaje | Received |
|
|||
| 1758-PB | VTE Prophylaxis in Patients with Lower Limb Immobilisation | Banah Khoshnaw | Received |
|
|||
| 1763-PB | Thromboembolic Complications Following Gender-Affirming Hormone Therapy In A Transfeminine Veteran Cohort | Eduarda Grinsztejn | Received |
|
|||
| 1764-PB | Newer Isn´t Always Safer: Real-World Venous Thromboembolism Risk Across Progestin Generations | Vanessa Velazquez | Received |
|
|||
| 1768-PB | Endogenous thrombin potential across polycystic ovary syndrome phenotypes: A French cross-sectional Study | justine HUGON RODIN | Received |
|
|||
| 1769-PB | Anticoagulation Practices During Ovarian Stimulation in Women at Risk for Thrombosis | Nikita Sareen | Received |
|
|||
| 1770-PB | The Progestin Paradox: Balancing Contraception and VTE Risk in Thrombophilia | Vanessa Velazquez | Received |
|
|||
| 1771-PB | Oral Contraceptives – A Genuine Thrombotic Risk or a Myth? | Maria Hulikova | Received |
|
|||
| 1773-PB | Management of Hormone Receptor Positive Breast Cancer in Thrombophilia: The need for data-driven guidelines | Hila Ghersin | Received |
|
|||
| 1784-PB | Significant Improvement in Heavy Menstrual Bleeding for Patients with Bleeding Disorders Managed in a Multidisciplinary Care Model | Vanessa Bouskill | Received |
|
|||
| 1785-PB | Current gynaecological management of women and girls with bleeding disorders in the United Kingdom: Evaluation of real-world clinical practice. | Laura Knox | Received |
|
|||
| 1798-PB | A platelet ß3 integrin phenotype that is associated with heavy menstrual bleeding | Aster E. Pijning | Received |
|
|||
| 1803-PB | Assesing Awareness and Knowledge of Bleeding Disorders in Girls and Women- Insights from a Cross-Sectional Survec at Ruhr University Bochum | June Schwarzbach | Received |
|
|||
| 1810-PB | Complement changes are identified by proteomics in pregnant individuals with antiphospholipid syndrome | Leslie Skeith | Received |
|
|||
| 1821-PB | Thromboembolic and Hemorrhagic Complications in Pregnant and Postpartum People with Sickle Cell Disease: A Retrospective Cohort Study | Ryan Hunt | Received |
|
|||
| 1822-PB | Socioeconomic Status and its Association with Venous Thromboembolism Risk During Pregnancy and Postpartum: Results from a Dutch Population-Based Study. | Judith Kooiman | Received |
|
|||
| 1825-PB | Coagulation Activation in Pregnant Women at high prothrombotic baseline risk | Luise Tittl | Received |
|
|||
| 1841-PB | Acquired Hemophilia A Postpartum: Clinical Management Challenges and Successful Outcomes | Gianluca Sottilotta | Received |
|
|||
| 1842-PB | Neuraxial anesthesia access in patients prescribed antepartum unfractionated heparin (UFH) versus low-molecular weight heparin (LMWH) | Arielle Langer | Received |
|
|||
| 1848-PB | Barriers to patient inclusion into a pregnancy trial: Pre-screening exclusions in the HYdroxychloroquine to improve Pregnancy outcome in women with AnTIphospholipid Antibodies (HYPATIA) trial | Karen Schreiber | Received |
|
|||
| 1852-PB | Venous thromboembolism risk stratification in multiple pregnancies during hospitalization in pregnancy and postpartum | Venina Barros | Received |
|
|||
| 1854-PB | DEATHS FROM OBSTETRIC EMBOLISM IN MINAS GERAIS, BRAZIL: EPIDEMIOLOGICAL ANALYSIS AND HEMOSTATIC PHYSIOPATHOLOGY (2020–2024) | Gabriely Silva | Received |
|
|||
| 1858-PB | Thrombelastography-based platelet mapping analysis can measure antiplatelet activity in pregnant individuals with antiphospholipid syndrome | Leslie Skeith | Received |
|
|||
| 1862-PB | ASSESSMENT OF THROMBIN GENERATION TEST USING AN AUTOMATED FLOUROGENIC ASSAY IN WOMEN WITH EARLY RECURRENT MISCARRIAGE | Carlos Aguilar | Received |
|
|||
| 1876-PB | Undiagnosed Congenital Thrombotic Thrombocytopenic Purpura Presenting as Peripartum Thrombotic Microangiopathy | Isabela Bumanlag | Received |
|
|||
| 2004-PB | Thrombocytosis Drives Alteration of Primary Hemostasis and the Occurrence of Acquired Von Willebrand Syndrome in Myeloproliferative Neoplasms | Gabriel Antherieu | Received |
|
|||
| 2006-PB | Cost-effectiveness analysis of upfront off-label emicizumab use in older individuals newly diagnosed with acquired hemophilia A hospitalized for bleeding control | Ming Yeong Lim | Received |
|
|||
| 2007-PB | 7 Year old patient with acquired hemophilia A managed successfully with emicizumab | Christopher Hugge | Received |
|
|||
| 2012-PB | When Lupus Anticoagulant Causes Bleeding: A Haemostatic Paradox in Paediatric Systemic Lupus Erythematosus - A Case Report and Literature Review | Julia Parra Serrano | Received |
|
|||
| 2015-PB | Clinical Characteristics and Outcomes of Acquired Hemophilia A Treated with Emicizumab: A Single-Center Case Series | Michael Recht | Received |
|
|||
| 2021-PB | Acquired von Willebrand Syndrome: cause of major bleeding in Ibrutinib-treated CLL | Darko Antic | Received |
|
|||
| 2023-PB | Transforming Care in Acquired Hemophilia A: A Digital Network for Remote Management | Marta Mattana | Received |
|
|||
| 2031-PB | Emicizumab in acquired von Willebrand syndrome: a case report. | Elizabeth Ryan | Received |
|
|||
| 2035-PB | Acquired Hemophilia: Report of 9 Cases at a Referral Hospital in the Dominican Republic | Ana Nadal Ponce | Received |
|
|||
| 2040-PB | A durable gene editing approach for Hemophilia A that enables curative levels of FVIII activity in non-human primates | Alan Brooks | Received |
|
|||
| 2042-PB | Three Year Outcomes and Vector Integration Following AAV Gene Therapy in Adult Hemophilia A Dogs | Paul Batty | Received |
|
|||
| 2047-PB | Efficacy of AAV-mediated FVIII transgene expression employing a short enhancer element from the human F8 locus | FATEME BABAHA | Received |
|
|||
| 2050-PB | A Psychosocial Care Framework for Haemophilia Gene Therapy | Simon Fletcher | Received |
|
|||
| 2056-PB | A case of phenotoxicity after fidanacogene elaparvovec: supratherapeutic FIX and multiple thromboembolisms after AAV gene therapy for haemophilia B | Zoë Marks | Received |
|
|||
| 2057-PB | Conceptualizing Gene Therapy Failure in Hemophilia: A Qualitative Study of Canadian Clinician Perspectives | Roy Khalife | Received |
|
|||
| 2059-PB | Efficacy and Safety of Adeno-associated Virus-Based Gene Therapies for Hemophilia B: a Systematic Review and Meta-Analysis | Feng Xue | Received |
|
|||
| 2064-PB | A Delphi consensus process on a globally aligned gene editing lexicon for haemophilia | Emma Plumbley | Received |
|
|||
| 2065-PB | Assessment of the Bleeding Phenotype Normality in People with Hemophilia A Treated with NXT007 Prophylaxis: Analysis of All-Bleed Data Comparing with Healthy Volunteers within the NXTAGE Study | Kazuki Kojima | Received |
|
|||
| 2067-PB | Canine FIXa homodimeric antibody reduces annualized bleeding and infusion rates in severe hemophilia A dogs with canine FVIII inhibitors | Timothy Nichols | Received |
|
|||
| 2068-PB | A Novel Functional Assay Using a Two-Step Diluted Prothrombin Time for Monitoring Marstacimab Therapy | Atsuo Suzuki | Received |
|
|||
| 2069-PB | Denecimig (Mim8) restores thrombin generation into the normal range in people with haemophilia A: Post hoc analysis of the phase 3 FRONTIER2, FRONTIER4 and FRONTIER5 studies | Alex Farrell | Received |
|
|||
| 2071-PB | Thrombin generation of hemophilia B-causing factor IX variants with non-factor therapies | Jacob Lund | Received |
|
|||
| 2072-PB | Denecimig (Mim8) tiered dosing achieves consistent exposure and bleed control in phase 3 FRONTIER studies | Alex Farrell | Received |
|
|||
| 2077-PB | Preliminary Evaluation of Circular mRNA–Encoded Coagulation Factors VII and IX in CHO Cells | Pansakorn Tanratana | Received |
|
|||
| 2082-PB | Generation of liver sinusoidal endothelial-like cells secreting coagulation factor VIII from human iPS cells toward the cell-based therapy for hemophilia A | Kohei Tatsumi | Received |
|
|||
| 2083-PB | Pharmacokinetic and Pharmacodynamic Characterization of VGA039, a Protein S-targeting Monoclonal Antibody, Supports Subcutaneous Every-4-Week Dosing for Routine Prophylaxis in Phase 3 VWD Trial | Kristen Jaworski | Received |
|
|||
| 2084-PB | A calibrator comparison: Efanesoctocog Alfa product specific calibrator Vs non-specific product calibrator material. FVIII activity data from a UK NEQAS BC survey. | Anna Williams | Received |
|
|||
| 2085-PB | Association of Concizumab with Tissue Factor Pathway Inhibitor (TFPI) within Platelets and the Extracellular Matrix (ECM) | Alan Mast | Received |
|
|||
| 2087-PB | Impact of Heat-Stable Factor VIII Mimetics and Replacement Therapies on Inhibitor Titer using a Modified Nijmegen-Bethesda Test Across Bovine Chromogenic FVIII Assays | Elaine Benoit | Received |
|
|||
| 2090-PB | Heat treatment for determination of emicizumab in presence of factor VIII activity - a way forward? | Adrian Alexander Kimiaei | Received |
|
|||
| 2091-PB | Effectiveness of a newly-formulated intranasal DDAVP compared with intranasal DDAVP and subcutaneous DDAVP in mild hemophilia A | Magdalena Lewandowska | Received |
|
|||
| 2093-PB | Effects of denecimig (Mim8) and tranexamic acid in an in vitro clot lysis assay | Marianne Kjalke | Received |
|
|||
| 2094-PB | Pharmacokinetics and inter-patient variability of Efanesoctocog alfa in a real-world cohort: a single centre experience | Anuradha Bhide | Received |
|
|||
| 2096-PB | Surgical prophylaxis with simoctocog alfa in people with severe haemophilia A on emicizumab prophylaxis: The NuPOWER study | Holly Maydew | Received |
|
|||
| 2099-PB | Hepatobiliary events in the Phase 3 ATLAS-OLE trial: 120-day safety update | Samantha Diorio | Received |
|
|||
| 2101-PB | Indirect treatment comparison of emicizumab versus efanesoctocog alfa prophylaxis in pediatric people with severe hemophilia A | Helen Miller | Received |
|
|||
| 2103-PB | Mental and emotional impact of emicizumab treatment in people with hemophilia A: post hoc analysis of the HAVEN 3 and 4 studies | Mark Skinner | Received |
|
|||
| 2104-PB | Bleeding event rates as a function of plasma emicizumab levels in a large cohort of children and adults with hemophilia A | Jerome Teitel | Received |
|
|||
| 2105-PB | Prevention of Bleeding in Patients with Moderate and Severe Hemophilia A Playing Sports: A Comparison between Factor VIII and Emicizumab Prophylaxis - STEP: SporTs Emicizumab Prophylaxis. - Interim Analysis | MEERA CHITLUR | Received |
|
|||
| 2106-PB | Retrospective, Real-World Study of Annual Bleeding Rate Changes Reported in the Microhealth Digital App by Patients with Hemophilia A Transitioning to Efanesoctocog Alfa | Meera Chitlur | Received |
|
|||
| 2107-PB | Mim8 (denecimig) prophylaxis in adults, adolescents and children with haemophilia A with or without inhibitors: Interim patient-reported outcomes from the long-term extension study (FRONTIER4) | Jack Lewis | Received |
|
|||
| 2108-PB | Bridging the Gap: A Calibration Model to Correct One-Stage Assay Underestimation of Efanesoctocog Alfa in Routine Clinical Practice | Te-Fu Weng | Received |
|
|||
| 2115-PB | Physicians´ Preferences in the Treatment of Hemophilia: A Discrete-Choice Experiment | Amy Behrenshausen | Received |
|
|||
| 2117-PB | Final Surgery Data from B-MORE: A 24-Month, Prospective, Non-Interventional Study of the Real-World Effectiveness and Usage of rFIXFc in Haemophilia B | Costello Medical | Received |
|
|||
| 2120-PB | Initiating emicizumab prophylaxis in children with haemophilia A in Australia: a cost-effectiveness analysis utilising real-world data | Elise Flynn | Received |
|
|||
| 2121-PB | Bleeding outcomes and quality of life: A sub-analysis of a non-interventional study of rVIII-SingleChain prophylactic treatment for haemophilia A | ISABEL AMY BLAIR | Received |
|
|||
| 2125-PB | IN VITRO THROMBIN GENERATION IN CONCIZUMAB COMBINATION THERAPY | Elena Monzón Manzano | Received |
|
|||
| 2126-PB | Safety and efficacy of the fitusiran antithrombin-based dose regimen people with hemophilia A and B by age group | Samantha Diorio | Received |
|
|||
| 2127-PB | Reasons for treatment preference in people with hemophilia A switching from factor VIII prophylaxis to emicizumab in the BEYOND ABR study: a detailed analysis | Helen Miller | Received |
|
|||
| 2133-PB | Preclinical Safety and Thrombotic Risk Assessment of the siRNA TGM-148 for Bleeding Disorders | Kaitlyn Calabro | Received |
|
|||
| 2135-PB | Protect-NOW: Real-world treatment of previously untreated and minimally treated patients with severe haemophilia A | Susan Halimeh | Received |
|
|||
| 2138-PB | A Real world evidence on patients´ preference among Chinese Adults and Adolescent Patients with Hemophilia on Marstacimab in Bo´ao pilot zone | Xinyan Wang | Received |
|
|||
| 2139-PB | Impact of cost-effectiveness in patients with hemophilia A who switched their prophylactic medicines to Efanesoctcog-alfa | Teruhisa Fujii | Received |
|
|||
| 2141-PB | Characterization of Novel Wound-healing Peptides from Animal Source | Lorena Kröner | Received |
|
|||
| 2142-PB | UK Laboratory Consensus on Coagulation testing of patients receiving marstacimab: Findings from the first structured review of BASIS clinical trial data | Gurveena Johal | Received |
|
|||
| 2144-PB | Real-world use of simoctocog alfa prophylaxis in severe haemophilia A: preliminary results from the Hungarian Long-Term Non-Interventional Investigation (Nuwiq NIS) | Holly Maydew | Received |
|
|||
| 2162-PB | Minimal Important Difference (MID) in Patient Reported Outcomes, Burdens and Experiences (PROBE) Score among People with Hemophilia. | Federico Germini | Received |
|
|||
| 2165-PB | Thrombin generation in patients with severe haemophilia A on efanesoctocog alfa prophylaxis | Petr Smejkal | Received |
|
|||
| 2168-PB | Real-World Pharmacokinetic Profiles of Recombinant and Plasma-Derived Factor VIII in Haemophilia A Using WAPPS-HEMO in a Single Centre in Chile | Angelica Valencia Guzman | Received |
|
|||
| 2171-PB | Marstacimab in Severe Haemophilia B without inhibitors: First UK Real-World Experience – A Case Series | Jireh Ann Batac | Received |
|
|||
| 2182-PB | Assess, Document, Prevent: VTE Risk Assessment Rates at a Rural Referral Hospital | Rachel Pittman | Received |
|
|||
| 2193-PB | From Vision to Reality: Advancing Nursing Care and Increased Access Through Rural Outreach and Strategic Partnerships | Louise Baca | Received |
|
|||
| 2194-PB | Evaluating Left Atrial Appendage Closure Devices as a Viable Option for Hemophilia Patients with Atrial Fibrillation Regardless of Inhibitor Status | Felicia Munster | Received |
|
|||
| 2197-PB | Specialist nurse led peri-operative anticoagulation management in complex cases | Paul Priest | Received |
|
|||
| 2199-PB | From local campaign to public policy: how the World Thrombosis Day bridge enabled municipal thrombosis awareness programs in small municipalities in Southern Santa Catarina (Brazil) | Ana Nazário | Received |
|
|||
| 2200-PB | Lyon, pet mascote of the Circulando Sempre project in Southern Brazil: early organic reach in 3 months to promote vascular health and thrombosis prevention | Ana Nazário | Received |
|
|||
| 2205-PB | Venous Stents in the Management of Post-Thrombotic Syndrome-Related Ulcers: A Systematic Review | Elise Thomson Moore | Received |
|
|||
| 2211-PB | Clinical and Laboratory Factors Associated With Pulmonary Embolism in Children With Lower-Extremity Deep Venous Thrombosis | Laura LaBarre | Received |
|
|||
| 2212-PB | Outcomes of endovascular interventions versus anticoagulation in adolescents with non-catheter associated iliofemoral deep venous thrombosis (DVT): a preliminary analysis of a multi-institutional cohort study | Eman Abdelghani | Received |
|
|||
| 2213-PB | Implementation of a Novel Point of Care Electronic Medical Record Best Practice Advisory to Improve Screening and Initial Evaluation of Adolescents with Heavy Menstrual Bleeding in a Primary Care Setting | Mariel Smith | Received |
|
|||
| 2217-PB | Transition Assessments Among Adolescents and Young Adults with Bleeding Disorders: An Ongoing Single Center Experience with a Structured Pediatric-to-Adult Transition Program | Deanna Maida | Received |
|
|||
| 2218-PB | Bleeding Severity, Iron Status, and Depression in Adolescents With Heavy Menstrual Bleeding | Divyaswathi Citla Sridhar | Received |
|
|||
| 2219-PB | Incidence of Platelet Disorders Among Adolescents and Young Adults with Heavy Menstrual Bleeding | Maria Carter Febres | Received |
|
|||
| 2221-PB | Iron carboxymatose is a safe and effective treatment for iron deficiency and anemia in adolescents with heavy menstrual bleeding | Marganit Benish | Received |
|
|||
| 2223-PB | Safety and Radiographic Outcomes of Anticoagulation in Neonatal Cerebral Sinus Venous Thrombosis – a Retrospective Cohort Study | Sriveda Boyalakuntla | Received |
|
|||
| 2226-PB | Fetal Torcular Herophili Thrombosis at 2nd trimester: Clinical Presentation, Management and Outcome | Eleftheria Lefkou | Received |
|
|||
| 2227-PB | A Rare Occurrence of Primary Neonatal Autoimmunity and Antiphospholipid Syndrome | Paige Severeid | Received |
|
|||
| 2233-PB | Rivaroxaban thromboprophylaxis in children with intestinal failure | Soumitra Tole | Received |
|
|||
| 2240-PB | Pediatric Antiphospholipid Syndrome: A Multicenter Retrospective Cohort Study | Angela Weyand | Received |
|
|||
| 2242-PB | Understanding contact risks of pediatric physical activity: video analysis to inform decisions for physical activity among children at risk of bleeding injuries | Lauren Backstein | Received |
|
|||
| 2246-PB | Real-World Inpatient Use of Antithrombin Concentrate Among Pediatric Patients in the United States, 2016–2025 | Wilton Rodriguez | Received |
|
|||
| 2247-PB | Multicenter Validation of a Pediatric Hospital-Wide Venous Thromboembolism Risk Assessment Model: A Children´s Healthcare Advancements in Thrombosis (CHAT) Study | Julie Jaffray | Received |
|
|||
| 2250-PB | INCIDENCE OF RECURRENT THROMBOSIS AND BLEEDING IN PEDIATRIC ONCOLOGY PATIENTS TREATED WITH DIRECT ORAL ANTICOAULANTS (DOACS)INCIDENCE OF RECURRENT THROMBOSIS AND BLEEDING IN PEDIATRIC ONCOLOGY PATIENTS TREATED WITH DIRECT ORAL ANTICOAULANTS (DOACS) | Linda Schiff | Received |
|
|||
| 2253-PB | Post-thrombotic syndrome and quality of life in pediatric patients following asymptomatic venous thromboembolism. Does asymptomatic thrombosis matter? | Vilmarie Rodriguez | Received |
|
|||
| 2262-PB | Triglycerides as risk factor for neonatal venous thrombosis; a case-control study | Irene Klaassen | Received |
|
|||
| 2268-PB | Accuracy and Precision of a Point-of-Care Meter for Monitoring activated Partial Thromboplastin Time in Children. | Joel Livingston | Received |
|
|||
| 2269-PB | Evaluating feasibility and acceptability of three common adherence measurement strategies for pediatric anticoagulants reveals variable data completion rates and acceptability | Lori Luchtman-Jones | Received |
|
|||
| 2275-PB | Evolution of Treatment Patterns in Moderate Hemophilia During Early Childhood: A Longitudinal Within-Patient Analysis | Shannon Carpenter Carpenter | Received |
|
|||
| 2281-PB | Community Versus Hospital Acquired Pulmonary Embolism In Children | John Puetz | Received |
|
|||
| 2286-PB | Pediatric Intracardiac Thrombosis: Treatment Approaches and Patient Outcomes at a Single Center | Oluwaseun Olaiya | Received |
|
|||
| 2289-PB | Anticoagulant adherence estimates in pediatric, adolescent, and young adult patients vary depending upon which of three common adherence measurements are utilized. | Lori Luchtman-Jones | Received |
|
|||
| 2296-PB | Off-Label Use of Ticagrelor in Pediatric Acute Ischemic Stroke Patients | Isabel Vega Calderon | Received |
|
|||
| 2297-PB | Real World Experience of Efanesoctocog Alfa in Irish Children with Severe Haemophilia A and High Intensity Sporting Activities | Saad Ahmed | Received |
|
|||
| 2298-PB | Challenges to Transcranial Doppler Screening for Stroke Prevention in Pediatric Sickle Cell Disease: A Cross-Sectional Survey in Saudi Arabia | Ohoud Kashari | Received |
|
|||
| 2299-PB | Infection-Triggered Coagulopathy with LAHPS-Like and ITP-Like Features: Successful IVIG Treatment Guided by Thromboelastography | Brandao Leonardo | Received |
|
|||
| 2311-PB | Association of Neutrophil Extracellular Trap Biomarkers with Catheter-Associated Deep Vein Thrombosis and Clinically Relevant Bleeding in Critically Ill Children | Anna Prykhodko | Received |
|
|||
| 2312-PB | Novel Off-label use of Cangrelor for prevention of hepatic artery thrombosis following pediatric liver transplantation | Dalia Bashir | Received |
|
|||
| 2315-PB | Limited Thrombin Generation Response to rFVIIa in a Type 3 von Willebrand Disease Patient with Inhibitor on Emicizumab: Implications for Perioperative Hemostasis | Jessica Garcia | Received |
|
|||
| 2316-PB | Multi-Center Study Validating the Domain-Sorted Kids ITP Tool (KIT 2.0) To Assess Health-Related Quality of Life (HRQoL) in Pediatric ITP | Rania Khelifi | Received |
|
|||
| 2318-PB | Subgaleal Hemorrhage associated with minor trauma as a presenting sign in two young children with mild hemophilia-A | Chris Hugge | Received |
|
|||
| 2333-PB | Successful rivaroxaban anticoagulation for a 3.5mm Blalock-Taussig-Thomas (BTT) shunt: A case report | Joel Livingston | Received |
|
|||
| 2337-PB | Congenital Thrombotic Thrombocytopenic Purpura with Chronic Kidney Disease in a Pediatric Patient: A Rare and Prolonged Clinical Course | Hermine Sayiyan | Received |
|
|||
| 2355-PB | ECMO for Pediatric Pulmonary Embolism: A Review of the ELSO Registry | Katherine Regling | Received |
|
|||
| 2356-PB | Use of Leukoreduced, Low-titer, Group O Whole Blood for Cardiopulmonary Bypass Priming and Postoperative Organ Dysfunction in Pediatric Cardiac Surgery: A Retrospective Cohort Study | Andrew Meyer | Received |
|
|||
| 2392-PB | CRISPR/Cas9-mediated deletion of Shp1 and Shp2 reveals a critical role for Shp2 in human megakaryopoiesis | Alexandra Mazharian | Received |
|
|||
| 2399-PB | Dynamic proteomic regulation of human megakaryocyte maturation and platelet biogenesis | Freda Passam | Received |
|
|||
| 2400-PB | Cellular and Molecular Characterization of Platelet Formation via Membrane Budding from IPSC-derived Megakaryocytes | Ponlapat Rojnuckarin | Received |
|
|||
| 2414-PB | Platelet Hyperreactivity in Pregnancy Increases the Risk of Ischemic Placental Disease | Jeffrey Berger | Received |
|
|||
| 2435-PB | Activated platelets are a major, previously unrecognised determinant of stem cell graft quality and neutrophil recovery in autologous transplantation | Philip Choi | Received |
|
|||
| 2436-PB | Mitochondrial permeability transition critically regulates of highly procoagulant platelet phenotypes | Joseph Aslan | Received |
|
|||
| 2465-PB | Quantitative Variability of Platelet MRP4 Expression in Acetylsalicylic Acid–Treated Patients and Its Association with Aspirin Responsiveness | Eleonora Schiera | Received |
|
|||
| 2475-PB | Platelet activation pathways are differentially modulated following varied storage conditions | Melissa Chan | Received |
|
|||
| 2479-PB | Female sex is associated with a hyperreactive platelet phenotype | Emily Mosher | Received |
|
|||
| 2481-PB | Temperature-Dependent Regulation of Platelet-Derived Extracellular Vesicles during Extended Apheresis Platelet Storage: Findings from the CHIPSiv Study | Susan Shea | Received |
|
|||
| 2487-PB | Extended cold storage favours the development of procoagulant platelets while suppressing apoptosis | Lacey Johnson | Received |
|
|||
| 2509-PB | Direct Antiplatelet Effects of the Dual Sodium Glucose Transporter Inhibitor (SGLT1 and SGLT2) Sotagliflozin Support its Use in Prevention of Thrombosis | Michael Holinstat | Received |
|
|||
| 2519-PB | Icosapent Ethyl Attenuates Thrombosis via EPA-Dependent, 12-Lipoxygenase–Mediated Platelet Inhibition | Krista Goerger | Received |
|
|||
| 2527-PB | Stalk Region of the aVß3 Integrin Molecule Modulates Ligand-Binding Activity | Oleg Kim | Received |
|
|||
| 2534-PB | Epitope of the Anti-Fc?RIIa Monoclonal Antibody IV.3 by Cryogenic Electron Microscopy (Cryo-EM), Surface Plasmon Resonance (SPR), Alchemical Free–Energy Calculations, and Molecular Dynamics Simulations: Implications for Therapy of Immunothrombosis | Barry Coller | Received |
|
|||
| 2538-PB | A Pivotal Role for MMP-9 in Spontaneous Left Atrial Appendage Thrombosis and Inflammation | Guy Reed | Received |
|
|||
| 2540-PB | FXII and Advanced Glycation End-Products Drive Hypercoagulability in Diabetes Mellitus. | Dillon Bohinc | Received |
|
|||
| 2565-PB | Occult Dysfunction: Trauma Milieu Reduces Healthy Platelet Viscoelastic Function and Immunothrombotic Expression yet Induces Shear-Mediated Hyperthrombosis | Aarushi Bajpai | Received |
|
|||
| 2567-PB | Challenging the prothrombotic hypothesis in never-hospitalised long covid: no evidence of hypercoagulability or association with microclots | Kher Lik Ng | Received |
|
|||
| 2586-PB | Acute Elevation of FVIII Occurs Without VWF in the Mouse Inflammatory Response | Anthony Guglya | Received |
|
|||
| 2587-PB | Descriptive Analysis of the Nationwide START2 Antiphospholipid Registry: Clinical and Laboratory Characteristics of 500 Patients with Persistently Positive Antiphospholipid Antibodies | Vittorio Pengo | Received |
|
|||
| 2588-PB | Beyond the Repeat Test: Clinical Predictors and Management Pitfalls of Indeterminate Lupus Anticoagulant Results | Morayma Reyes-Gil | Received |
|
|||
| 2589-PB | Hip Fracture Surgery is Associated with Inflammation-mediated Hypercoagulability Compared with Elective Total Hip Arthroplasty | Prism Schneider | Received |
|
|||
| 2628-PB | Cancer-Associated thrombosis Anticoagulation Interruption outcomes. Sub analysis of ADAM and EVE trials. | Alfonso Tafur | Received |
|
|||
| 2629-PB | Reassessing Venous Thromboembolism Risk During Hospitalization to Enhance Appropriate Thromboprophylaxis in Medical Inpatients | Liv Mahler | Received |
|
|||
| 2630-PB | Therapeutic Challenges and Comparative Outcomes of Antithrombotic Therapy in Lupus Anticoagulant–Associated Stroke: A Systematic Review | Anchu Vincent | Received |
|
|||
| 2632-PB | Patient Comprehension of Perioperative Anticoagulation Instructions | Sara Philip | Received |
|
|||
| 2636-PB | Concordance of Recommendations from a Computerized Decision Support System for Periprocedural Anticoagulant Management with Clinical Practice Decisions and Evidence-Based Guidelines in a Non-Academic and an Academic Center | Amulya Bhagirath | Received |
|
|||
| 2642-PB | Opening the Guideline "Black Box": Chance-Corrected Agreement and Error Impact Between ASH Thrombophilia Recommendations and Decision Models | Ben Djulbegovic | Received |
|
|||
| 2643-PB | Patterns and Outcomes of Thrombolytic Therapy for Pulmonary Embolism: A Single-Center Experience | James Ching Shih | Received |
|
|||
| 2665-PB | Development of globally aligned factor XI inhibitor lexicon for healthcare practitioners | Emma Plumbley | Received |
|
|||
| 2669-PB | Targeted thrombolysis using Red Blood Cell Vesicles enables lysis of platelet-rich human ex-vivo thrombi | Diya Agrawal | Received |
|
|||
| 2679-PB | A Two-Period, Randomized, Double-Blind, Cross-over Study in Healthy Subjects Investigating Pharmacokinetic and Pharmacodynamic Equivalence and Safety of Two Recombinant tPA Presentations, PBS tPA versus Actilyse, at Two Subtherapeutic Dose Levels | Katarina Miljevi&263; | Received |
|
|||
| 2686-PB | SCOPE TXA: Sickle Cell Observations of Provider Experiences with Tranexamic Acid | Gianna Valenti | Received |
|
|||
| 2716-PB | In-vitro evidence on time- and dose-dependent release of Heparin (UFH or LMWH) neutralized by Protamine Sulfate and impact on hemostasis assays | Nicolas Bouveyron | Received |
|
|||
| 2718-PB | Anti-HPF4:Anti-PF4 A450 Elisa ratio to differentiate VITT or PF4 dependent thrombocytopenias/thrombosis without heparin from HIT | Jean Amiral | Received |
|
|||
| 2725-PB | Antithrombin Deficiency in Critically Ill Patients Is Associated with Reduced Heparin Efficacy and Failure to Achieve Anti-Xa Targets | Mirjam Bachler | Received |
|
|||
| 2741-PB | Clot on the Clock: Timing of Anticoagulation and Outcomes in PE | Salem Kim | Received |
|
|||
| 2742-PB | Method Comparison of the Revohem Anti-Xa LRT assay Compared to Other Commercial Reagents – Monitoring of Unfractionated and Low Molecular Weight Heparin | Thomas Pitchford | Received |
|
|||
| 2743-PB | Direct Oral Anticoagulant Use in Patients with End Stage Renal Disease on Dialysis: A Survey of Canadian Hematologists and Nephrologists | Anna R. Blankstein | Received |
|
|||
| 2747-PB | Does Routine Doppler Ultrasound Screening Reduce Clinically Relevant Thromboembolic Outcomes in Spinal Cord Injury Patients Receiving Standard Thromboprophylaxis? | Efrat Burshtein | Received |
|
|||
| 2751-PB | First Dose Low Molecular Weight Heparin Treatment Anti-Xa Measurements for Acute Pulmonary Embolism or Atrial Fibrillation | Bruce Davidson | Received |
|
|||
| 2758-PB | Method Comparison of the Revohem Anti-Xa LRT assay Compared to Other Commercial Reagents – Monitoring of Xa-Direct oral anticoagulants | Thomas Pitchford | Received |
|
|||
| 2759-PB | Low Molecular Weight vs Unfractionated Heparin and 30-Day PE-Associated Mortality | Kelsey Bria | Received |
|
|||
| 2770-PB | Evaluation of Apixaban Dosing Practices for unprovoked VTE/PE in Medically Complex Patients | Thalia Padilla Kelley | Received |
|
|||
| 2787-PB | Thrombotic Events and Anticoagulation Strategies in Acute Leukemia: A Single-Center Real-World Case Series | Emir Hajdarevi&263; | Received |
|
|||
| 2791-PB | Mechanistic study of the antivirulence activity of ticagrelor against Staphylococcus aureus at antiplatelet dosage | Florence Putters | Received |
|
|||
| 2792-PB | Agonist-Specific Platelet Hyperreactivity and Long-Term Cardiovascular Mortality: A Regional Retrospective Record-Linkage Study | Fabio M. Pulcinelli | Received |
|
|||
| 2793-PB | Enterococcus faecalis-induced infective endocarditis: first mechanistic insights and role of ticagrelor | Minoo Jafarzadeh | Received |
|
|||
| 2796-PB | Platelet reactivity with clopidogrel versus low-dose prasugrel in elective endovascular treatment for intracranial aneurysms: automated LTA and a cartridge-based P2Y12 assay | Miyu Kitagami | Received |
|
|||
| 2799-PB | Platelet MRP4 Expression in Aspirin-Treated T1DM Patients Is Associated With Higher Aspirin Efficacy Compared with T2DM | Simone De Corci | Received |
|
|||
| 2802-PB | Stable expression of ATIII in non-human primates by CRISPR-mediated gene knock-in for the treatment of inherited thrombophilias. | Kate Senger | Received |
|
|||
| 2807-PB | A Novel Monoclonal Antibody (cenvacibart) Targeting FXI Reduces Clotting During Hemodialysis Ex vivo | Katarina Miljevi&263; | Received |
|
|||
| 2808-PB | Decoupling thrombosis from hemostasis: the effect of milvexian on thrombus burden and thrombin generation in the phase 2 AXIOMATIC-TKR study | Noah Cook | Received |
|
|||
| 2809-PB | Selective Bypassing Approaches for Long-Acting Factor XI Antibody Therapeutics | Christina Lorentz | Received |
|
|||
| 2810-PB | Bleeding risk associated with Factor XI (FXI) monoclonal antibodies (mAbs) in combination with aspirin (ASA) in healthy volunteers and post-orthopaedic surgery patients: Analysis from recent Phase 1 and 2 studies | Emma Plumbley | Received |
|
|||
| 2812-PB | Mechanistic population pharmacokinetic/pharmacodynamic (PK/PD) modelling of Factor XI (FXI)-targeting monoclonal antibodies (Abs) supports durable anticoagulant coverage and translational dose and regimen selection | Emma Plumbley | Received |
|
|||
| 2813-PB | Mechanistic population pharmacokinetic/pharmacodynamic and time-to-event modelling support sustained Factor XI inhibition and superior post-operative venous thromboembolism prevention with REGN7508CAT | Emma Plumbley | Received |
|
|||
| 2816-PB | Evaluation of Commercially Available Bypassing Strategies for Long-Acting Factor XI Antibodies | Michael Wallisch | Received |
|
|||
| 2822-PB | Factor XIA Inhibition with Asundexian in Acute Non-Cardioembolic Stroke or High-Risk Transient Ischemic Attack: Primary Results of the OCEANIC-STROKE Trial | Anna Wislocki | Received |
|
|||
| 2829-PB | Investigating the factor XI(a) anticoagulants milvexian and abelacimab through thrombinography and fibrinography: challenges and insights | henri THONON | Received |
|
|||
| 2840-PB | Assessment of Platelet Thrombus Formation in Response to JAK inhibitor using Total Thrombus-formation Analysis System (T-TAS) | Daisuke Hiraoka | Received |
|
|||
| 2848-PB | Micronized Purified Flavonoid Fraction for the Treatment of Post Thrombotic Syndrome: The MUFFIN-PTS randomized placebo-controlled trial | susan kahn | Received |
|
|||
| 2849-PB | Mechanical thrombectomy with anticoagulation versus anticoagulation alone for iliofemoral deep venous thrombosis: A single centre prospective cohort study | Sophie Zhong | Received |
|
|||
| 2856-PB | Application of the HERDOO2 Clinical Decision Rule Using Non-VIDAS® D-dimer assays in the DODS Study Population | Marc Rodger | Received |
|
|||
| 2858-PB | Patient-reported outcomes after upper-extremity deep vein thrombosis due to compression syndromes: A multinational longitudinal retrospective study | Maya Abrishami Kashani | Received |
|
|||
| 2867-PB | Beyond Hemodynamics: Coagulation–Fibrinolysis Biomarker Changes during Balloon Pulmonary Angioplasty in CTEPH—A Cohort Study | Theodora Kostelidou | Received |
|
|||
| 2879-PB | Balancing the Scales: Anticoagulation Challenges in Portal vein thrombosis – A Case Series | Chathurma Piyarathna | Received |
|
|||
| 2880-PB | Diagnostic delay, phenotypes, venous extension, recanalization and disability in cerebral venous thrombosis: a real-world single-center cohort. | Alejandro Godoy | Received |
|
|||
| 3001-PB | Effect of PCC on Thrombin Generation in Patients on Factor Xa Inhibitors with Bleeding or Needing Urgent Surgery (GAUGE): A Prospective Observational Cohort Study | Joseph Shaw | Received |
|
|||
| 3002-PB | Refinement of Risk Factors for Anticoagulant-related Bleeding Improves Discrimination | Kristen Sanfilippo | Received |
|
|||
| 3017-PB | Management of Anticoagulation for Patients with Primary Brain Tumors or Metastases: A Survey of Neurosurgeons and Anticoagulation Experts | Jordan Schaefer | Received |
|
|||
| 3019-PB | Impact of a Multidisciplinary Heart Failure Program on Anticoagulation Adherence in Patients with Atrial Fibrillation: Experience from a University Hospital in Saudi Arabia | Fakhr Alayoubi | Received |
|
|||
| 3037-PB | Short-term trajectories of sepsis-induced coagulopathy and patient outcomes: a retrospective cohort study using the MIMIC-IV database | Tomoki Tanigawa | Received |
|
|||
| 3038-PB | Experience in the use on emicizumab as prophylaxis of bleeding from de Spanish Acquired Haemophilia A Registry (SAHAR). | Maria Eva Mingot Castellano | Received |
|
|||
| 3039-PB | Component-Based Phenotypes of Sepsis-Associated Disseminated Intravascular Coagulation and Clinical Outcomes Under the JAAM-2 Criteria | Tomoki Tanigawa | Received |
|
|||
| 3046-PB | Thrombosis, bleeding, and mortality in patients with sepsis-inducedcoagulopathy: Analysis of a prospective cohort | Walter Ageno | Received |
|
|||
| 3047-PB | Early prothrombin time-international normalized ratio (PT-INR) trajectories identifydistinct coagulopathy phenotypes and predict mortality in sepsis: A prospective observationalstudy | Walter Ageno | Received |
|
|||
| 3049-PB | Compound Heterozygous Factor VII Deficiency Unmasked by Superwarfarin Intoxication in a Child | Te-Fu Weng | Received |
|
|||
| 3050-PB | A multinational, open-label study to investigate efficacy and safety of denecimig (Mim8) in adults with acquired haemophilia A: study enrolment 2026 | Ami Young | Received |
|
|||
| 3055-PB | Scurvy: An Overlooked Cause of Major Hemorrhage and Venous Thromboembolism. | Jacob Levites | Received |
|
|||
| 3058-PB | Thromboelastography (TEG) and point-of-care (POC) platelet function tests predict hematoma expansion in patients with spontaneous intracerebral hemorrhage (ICH) | Paul Lindholm | Received |
|
|||
| 3063-PB | Thromboembolic Events and Mortality in Cold Agglutinin Disease: A European Retrospective Cohort Study | Lily Ward | Received |
|
|||
| 3070-PB | Correction of severe hypofibrinogenemia with remission of myelodysplastic syndrome in a senile patient | XU YE | Received |
|
|||
| 3078-PB | Low-density lipoproteins as a biomarker for post-injury complications in traumatically injured patients. | Susan Shea | Received |
|
|||
| 3083-PB | Horizontal stacking as a practical storage configuration for maintaining platelet quality during cold storage | Lacey Johnson | Received |
|
|||
| 3084-PB | Machine processing of whole blood using a filtration-based autotransfusion device | Manfred Rauh | Received |
|
|||
| 3085-PB | Hemostatic Evaluation of Lyophilized SynthoplateTM via Intravenous and Intraosseous Route in Rabbit Models of Hemorrhage | Matthew Neal | Received |
|
|||
| 3087-PB | Retrospective audit of Massive Transfusion Protocol activations in critical obstetric bleeding in an Australian quaternary obstetric centre | emily powley | Received |
|
|||
| 3089-PB | When Less Is Enough: Challenging Platelet Dogma in Lumbar Puncture Safety | Richard Berish | Received |
|
|||
| 3092-PB | Postoperative Hemorrhage Following Fibrinogen Concentrate Versus Cryoprecipitate Use in Major Cardiovascular Surgery: A Real-World Analysis | David Gomez-Ulloa | Received |
|
|||
| 3094-PB | Perioperative Management of Anticoagulation in Patients with Mechanical Heart Valves | Joseph Shaw | Received |
|
|||
| 3095-PB | An intervention in search of an indication: A systematic review and meta-analysis of randomised trials of plasma transfusion | Jeannie Callum | Received |
|
|||
| 3108-PB | Withholding warfarin three or five days before high-bleed-risk procedures in patient self-managers | Nikolaj Nytofte | Received |
|
|||
| 3115-PB | Measurement of thrombin generation and factor V activity after prophylactic plasma treatment in a child with severe coagulation factor V deficiency | Carola Elisabeth Henriksson | Received |
|
|||
| 3121-PB | Identification of Significant Sex Specific F5 Expression Differences in Mice | Adrianna Jurek | Received |
|
|||
| 3123-PB | Elevated Fibrinogen as a Confounder in Thrombin Time-Based Heparin Screening | Bastian Bernhardt | Received |
|
|||
| 3128-PB | AFSTYLA® (rVIII-SingleChain) demonstrates high adherence, effective bleed control,and superior weight-adjusted cost efficiency in prophylaxis for hemophilia A in realworldclinical practice | Mariana Canaro | Received |
|
|||
| 3131-PB | Real-World Safety Profile of Direct Oral Anticoagulants (DOACs) in Saudi Arabia: A Retrospective Cross-Sectional Study | Fakhr Alayoubi | Received |
|
|||
| 3142-PB | Fresh Sample Stability of Human Citrated Plasma Samples (Native and Contrived) Measured Using a Chromogenic Factor IX Assay | Daniela Velasco | Received |
|
|||
| 3144-PB | Effect of Prekallikrein and HMWK Deficiencies on aPTT Assays | Bastian Bernhardt | Received |
|
|||
| 3163-PB | Conformational Regulation of Factor V Cofactor Activity by the B Domain: An Atomic Force Microscopy Structural Study | Anna Protopopova | Received |
|
|||
| 3181-PB | Reversal of Perinatal Lethal Thrombosis in Mice Carrying a Noncoding Chromosome 3 Variant Influencing Tissue Factor Expression | Arina Rodionova | Received |
|
|||
| 3182-PB | Factor V inhibits tissue factor-initiated coagulation through inhibition of factor X activation and modifies thrombin generation in hemophilia A | Keith Neeves | Received |
|
|||
| 3186-PB | Factor sensitivity of PT Rec and PT Owren for factors II, V, VII, and X | Bastian Bernhardt | Received |
|
|||
| 3188-PB | AI guided point of care ultrasound enables non specialists to safely rule out proximal deep vein thrombosis: diagnostic accuracy with implications for reducing diagnostic delay, thromboembolic complications, and unnecessary anticoagulation. | Maria rita Peralta | Received |
|
|||
| 3191-PB | Machine Learning Models to Predict Extremes of Platelet Function | Praveen Puviindran | Received |
|
|||
| 3197-PB | External Validation of a Machine Learning Model for Thrombotic Recurrence Risk Stratification in Thrombotic Antiphospholipid Syndrome | Ihosvany Fernández Bello | Received |
|
|||
| 3199-PB | Clinical Phenotype Characterization of Hemophilia A and B Using Contextual Natural Language Processing (DrBERT) on Electronic Medical Records | Perrine Warter | Received |
|
|||
| 3244-PB | Genomic characterization of Pediatric VTE identifies existing genome-wide association study variants from adult studies that are enriched in children with recurrent VTE. | Steven Bruzek | Received |
|
|||
| 3248-PB | Impact of genetic testing panels for patients with bleeding disorder of unknown cause: a single-center review | Ellen Cusano | Received |
|
|||
| 3253-PB | Long-read sequence analysis confirms that severe canine hemophilia A is caused by a genomic rearrangement closely mimicking the human intron 22 inversion variant | Nathalie Tijet | Received |
|
|||
| 3254-PB | Cytokine-induced Chromatin Accessibility in Whole Blood Neutrophils Links to Sepsis Transcriptional States | Justin Cayford | Received |
|
|||
| 3255-PB | Multi-omic characterization of pediatric venous thromboembolism (VTE) identifies methylation and proteomic signatures that correspond with known pathways. | Steven Bruzek | Received |
|
|||
| 3259-PB | Findings from the South Texas Family Study (STFS)—Designed to Identify Genetic and Environmental Determinants of Cardiovascular Disease (CVD) in High-Risk Mexican American (MA) Population—Demonstate the Importance of Exploring Both Sides of the Thrombo-He | Henry Mead | Received |
|
|||
| 3273-PB | Validation of a microfluidic assay for assessing platelet thrombi adhesion under shear stress | Yishi Tan | Received |
|
|||
| 3279-PB | Assessment of Sample Stability of Factor Assays on Sysmex CN6000 | Lee Beckett | Received |
|
|||
| 3282-PB | Joint Health Outcomes With Efanesoctocog Alfa Prophylaxis for Patients With Severe Hemophilia A: Third Interim Analysis of the Phase 3 XTEND-ed Study | Shanen Collins | Received |
|
|||
| 3288-PB | BIOmarkers of Inflammation and Bone Health in Patients with HEMophilia A: BIOHEMA: A Pilot Study | Katherine Regling | Received |
|
|||
| 3293-PB | Baseline Characteristics of Patients Switching to Prophylactic Efanesoctocog Alfa Therapy Evaluated for Joint Health in Hemophilia A in Taiwan (PROTECT-ALT Study) | Shanen Collins | Received |
|
|||
| 3298-PB | Impact of age, BMI, hypertension, and factor levels on joint health in mild hemophilia A | Harish Eswaran | Received |
|
|||
| 3302-PB | Prospective assessment of clinical frailty score in people with haemophilia. | Elizabeth Ryan | Received |
|
|||
| 3309-PB | AOZORA: safety and joint health outcomes over 6 years in children with hemophilia A – preliminary report from an early cohort | Helen Miller | Received |
|
|||
| 3312-PB | Osteoporosis and osteopenia in moderate and severe haemophilia: prevalence and longitudinal changes - a single centre experience | Anuradha Bhide | Received |
|
|||
| 3324-PB | Interim analysis of the A-MORE real-world study: 4-year treatment outcomes with a recombinant factor VIII Fc in the overall and non-severe populations | Liz Beatty | Received |
|
|||
| 3335-PB | Bridging the Gap: Physical Activity Perspectives in People with Hemophilia | Roy Khalife | Received |
|
|||
| 3343-PB | Exploring Patient Baselines in Primary-Care Settings and Opportunities for Enrichment in Severity-Focused Haemophilia Data | Kim Summers | Received |
|
|||
| 3356-PB | A sub analysis of historical symptoms and medical interventions in subjects with type 1 plasminogen deficiency (PLGD-1) prior to plasminogen replacement therapy | Karen Thibaudeau | Received |
|
|||
| 3359-PB | Accurately inferring missing factor VIII concentrate dosing information from health-record data in patients with haemophilia A. | Alexander Janssen | Received |
|
|||
| 3364-PB | Real-World use of a Novel Outcome Indicator Reflecting Patient Perspectives to Support Value-Based Healthcare Decision-Making in Haemophilia A in Italy: the HemPROve Non-Interventional Study | Giancarlo Castaman | Received |
|
|||
| 3370-PB | Assessment of Artificial Intelligence Capabilities in Predicting Pharmacokinetic Curves in Patients with Hemophilia | Gianluca Sottilotta | Received |
|
|||
| 3371-PB | Gender Differences in Disease Burden and Quality of Life in Hereditary Factor X Deficiency: Findings from the Hereditary Factor X Deficiency in America Survey | Kim Clark | Received |
|
|||
| 3374-PB | A new factor X mutant with decreased activity and binding to Calcium and Phospholipids and impact on laboratory assays | Jean AMIRAL | Received |
|
|||
| 3375-PB | In vitro study to evaluate the haemostatic effect of eptacog beta in patients with factor VII deficiency using global coagulation assays | Paula Acuña | Received |
|
|||
| 3377-PB | Characterising a cohort of Bleeding Disorders of Unknown Cause using modified Rotational Thromboelastometry; Thrombin Generation Assay and a Health related Quality of Life Questionnaire | Daniel Farrugia | Received |
|
|||
| 3395-PB | Type II Factor X Deficiency Due to the Roma Variant (p.Thr358Met): First Reported Cases From the United Arab Emirates Treated With Plasma-Derived Factor X Concentrate | Muna Adam | Received |
|
|||
| 3405-PB | Evaluation of the effect of direct oral anticoagulants on thrombin generation in haemophilia A | Anne Riddell | Received |
|
|||
| 3412-PB | Development and internal validation of a risk score for predicting surgical complications in patients with bleeding disorders | Omotola Olasupo | Received |
|
|||
| 3413-PB | Denecimig (Mim8) enhances in vitro thrombin generation in von Willebrand disease type 3 plasma | Jacob Lund | Received |
|
|||
| 3417-PB | Evidence of efficacy for prophylaxis with plasma-derived VWF/FVIII 1:1 in children with severe von Willebrand Disease: WIL-33 extends WIL-31 paediatric findings to <6 years | Holly Maydew | Received |
|
|||
| 3419-PB | The Burden of Joint Bleeding and Arthropathy in von Willebrand Disease:Systematic Review and Meta-analysis | Noah Sabbagh | Received |
|
|||
| 3420-PB | Qualitative Study Exploring the Lived Experiences of Adolescents and Adults with von Willebrand Disease Treated with VGA039 and Their Families in the VIVID-3 Phase 1/2 Clinical Study | Kristen Jaworski | Received |
|
|||
| 3421-PB | Real-world pharmacokinetics of von Willebrand factor/factor VIII concentrate (ratio 1:1) in the perioperative setting | Sjoerd Koopman | Received |
|
|||
| 3423-PB | Postpartum Haemorrhage and Haemostatic Management in Women With von Willebrand Disease: Results from the WiSH-QoL study | Marie-Hélène ANDRE-BONNET | Received |
|
|||
| 3424-PB | The economic burden of von Willebrand Disease in the United Kingdom: Insights from the PIVOT-vWD UK cohort | George Morgan | Received |
|
|||
| 3429-PB | Association of Social Risk Factors with Clinical Outcomes and Healthcare Utilization in von Willebrand Disease: A Medicaid Claims Analysis | Shreya Agarwal | Received |
|
|||
| 3430-PB | Routine Prophylaxis with Recombinant von Willebrand Factor in People with Clinically Severe von Willebrand Disease in a Real-World Setting: Final Analysis of ATHN 9, a Natural History Study for People with Severe VWD | Robert Sidonio | Received |
|
|||
| 3431-PB | Challenges for pharmacokinetic-guided dosing of plasma-derived VWF/FVIII 1:1 concentrate: insights from a population pharmacokinetic model | Jelien den Hollander | Received |
|
|||
| 3434-PB | Adolescent and Adult Perspectives on Menstrual Bleeding in von Willebrand Disease: The results from the WiSH-QoL study | Marie-Hélène ANDRE-BONNET | Received |
|
|||
| 3435-PB | Von Willebrand Factor (VWF) replacement therapy may be necessary in type 1 von Willebrand disease (VWD): Results from a French post-marketing study (PMS) of a low-FVIII VWF concentrate. | Thierry Leroi | Received |
|
|||
| 3436-PB | Validation of the predictive performance of a new population pharmacokinetic model of a highly pure plasma-derived von Willebrand factor: The real-world perioperative WIL-PKPOP-CHIR study | Marie-Hélène ANDRE-BONNET | Received |
|
|||
| 3458-PB | Assessment of bleeding in patients with chemotherapy induced thrombocytopenia treated with romiplostim | Laurent Frenzel | Received |
|
|||
| 3461-PB | Acquired Platelet Storage Pool Disorders in Patients with Chronic Myeloid Disorders | Meera Sridharan | Received |
|
|||
| 3466-PB | a-Granule secretion defects dominate longitudinal platelet dysfunction in Gaucher disease | Shoshana Revel-Vilk | Received |
|
|||
| 3467-PB | Heterogeneity of Anti-GPVI Antibody Binding Sites and Clinical Phenotypes in GPVI Deficiency | Midori Koike | Received |
|
|||
| 3474-PB | Effects of Tranexamic Acid in Patients with Hematological Malignancy and Severe Thrombocytopenia: A Systematic Review and Meta-analysis | Zainab Al-Housni | Received |
|
|||
| 3476-PB | UK NEQAS Platelet Light transmission Aggregation scheme uses GpIIbIIIa antagonist pellet, as a source of pathological control for external quality assessment | CHRISTOPHER REILLY-STITT | Received |
|
|||
| 3478-PB | Assessment of cardiopulmonary bypass-induced platelet disorders using the Quantra Qplus system: The PLAQUA Study | Margot Caron | Received |
|
|||
| 3491-PB | DENGUE LETHALITY IN UBERLÂNDIA, MINAS GERAIS, BRAZIL: EPIDEMIOLOGICAL ANALYSIS OF 134,506 REPORTED CASES (2016–2026) | Raissa de Novais | Received |
|
|||
| 3495-PB | Substantial Bleeding Burden and Limited Prophylaxis Use in Glanzmann Thrombasthenia: Prospective Real-World Data from ATHN Transcends | Divyaswathi Citla Sridhar | Received |
|
|||
| 3505-PB | Inherited Platelet Disorders in Spain: Epidemiology, clinical and laboratory complexity, and genetic landscape from RETPLAC registry | Daniel Zaldumbide | Received |
|
|||
| 3516-PB | Identification of Novel NBEAL2 Variants and Functional Characterisation of Grey Platelet Syndrome in Four Unrelated Pedigrees | Daniel Zaldumbide | Received |
|
|||
| 3536-PB | HEAVY MENSTRUAL BLEEDING IN HEREDITARY THROMBOCYTOPENIA: A SIGNIFICANT AND UNDERRECOGNIZED CLINICAL BURDEN | CRISTINA PASCUAL IZQUIERDO | Received |
|
|||
| 3539-PB | A Unique Case of Coexisting von Willebrand Disease, ß-Thalassemia Minor, MEFV Mutation, and Severe Platelet Aggregation Defect in a Pediatric Patient | Robert Tadevosyan | Received |
|
|||
| 3546-PB | A case of SLFN14-related thrombocytopenia with novel variant Glu253del and abnormal platelet aggregometry | Alexander Wathen | Received |
|
|||
| 3556-PB | Platelet histogram: a tool for distinguishing causes of chronic thrombocytopenia | Imogen Welding | Received |
|
|||
| 3566-PB | Heterozygous GP1BA Variant Associated with Mild Macrothrombocytopenia and Low Bleeding Risk: Clinical and Molecular Characterization | Rosa Sonja Alesci | Received |
|
|||
| 3587-PB | Acute promyelocytic leukemia with myelofibrosis and thrombocytosis: does the MPL gene mutation play a role? | Xu Ye | Received |
|
|||
| 3591-PB | Analysis of 370 Variants Within an ADAMTS13 Database Extends Understanding of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) | Matthew Carter | Received |
|
|||
| 3592-PB | Endothelial function in patients with immune Thrombotic Thrombocytopenic Purpura in clinical remission: an office-based, non-invasive test feasibility study | Marina Beltrami Moreira | Received |
|
|||
| 3596-PB | Comparing the Length of C5 Inhibitor Treatment Duration in Patients with Newly Diagnosed Atypical Hemolytic Uremic Syndrome | Lucas Wang | Received |
|
|||
| 3626-PB | Myeloid mutations as predictors of arterial thromboembolism in myeloproliferative neoplasms | Thomas Fusillo | Received |
|
|||
| 3629-PB | Neutrophil extracellular trap formation is increased in patients with myeloproliferative neoplasms and decreases with cytoreductive treatment | Ingrid Lundahl | Received |
|
|||
| 3630-PB | Hemostatic biomarker expression across various cancer types and disease stages: a prospective study involving 4,292 patients from the HYPERCAN Study | Patricia Gomez Rosas | Received |
|
|||
| 3636-PB | Comparison of ROTEM in patients with myeloproliferative neoplasms and controls with non-clonal polycythemia and/or thromboleukocytosis and following initiation of cytoreduction | Alsu Gatina | Received |
|
|||
| 3637-PB | Thrombotic Risk in a Plasma Cell Disorder Cohort: An Analysis of CHIP Mutations Affecting Platelet Count and Function | Ritika Vankina | Received |
|
|||
| 3639-PB | Bleeding Events in Patients with Multiple Myeloma Treated with BCMA-Directed CAR T-CellTherapy: A Systematic Review of Clinical Trials | vandreden patrick | Received |
|
|||
| 3657-PB | Multidomain Patient-Reported Outcome Impairment in Adults with Antiphospholipid Syndrome Using PROMIS-29+2: An International Cross-Sectional Study | Chanakya Nayudu | Received |
|
|||
| 3671-PB | Coagulation Factor VIII expression is tightly regulated by MALAT1/ETS1/ETS2 regulatory complex in human vascular endothelial cells | Samaneh Abdolalizadeh | Received |
|
|||
| 3677-PB | Single-cell RNA sequencing reveals aberrant function of bone marrow endothelial cells in the precursor stages of multiple myeloma | Xueyan Cui | Received |
|
|||
| 3686-PB | Plasminogen Activator Inhibitor-1 as a Determinant of Septic Shock Outcomes | vandreden patrick | Received |
|
|||
| 3692-PB | Inflammation Uncouples F8 and VWF Expression in Human Lymphatic Endothelial Cells | Anthony Guglya | Received |
|
|||
| 3702-PB | The role of imanixil in cell-free hemoglobin clearance in Sickle cell disease | Tirthadipa Pradhan-Sundd | Received |
|
|||
| 3703-PB | Microparticle tissue factor activity for assessing thrombotic risk and monitoring treatment in patients with multiple myeloma. | vandreden patrick | Received |
|
|||
| 3706-PB | Tissue Factor–Positive Microparticles Promote Thromboinflammation and associate with Disseminated intravascular coagulation, and Mortality in Sepsis | vandreden patrick | Received |
|
|||
| 3710-PB | Comprehensive multi-parameter characterization of circulating extracellular vesicles from patients with bicuspid aortic valves reveals increased platelet activation and endothelial dysfunction. | Luisa Weiss | Received |
|
|||
| 3718-PB | After weight loss through metabolic bariatric surgery in patients with obesity and T2D extracellular vesicles associated with platelet activation, endothelial function and macrophages improve. | Maja Andersson | Received |
|
|||
| 3719-PB | Extracellular Vesicle Concentration and Thrombin Generation: A Comparison of Red Cell and Platelet Concentrate Units | Jamie Nash | Received |
|
|||
| 3720-PB | Thrombomodulin acts as a rheostat of COVID19-Associated coagulopathy severity in K18-hACE2 mice | Roberto Aiolfi | Received |
|
|||
| 3722-PB | Pharmacologic Blockade of C5a–C5aR1 Signaling Attenuates Coagulopathy, Endothelial Injury, and Mortality in Experimental Staphylococcus aureus Sepsis | Florea Lupu | Received |
|
|||
| 3725-PB | Impact of secondary infections on the host response to sepsis in young and aged mice | Angela Bilic | Received |
|
|||
| 3727-PB | Characterization of immunothrombosis in a murine model of pneumococcal respiratory sepsis | Jennifer Viksne | Received |
|
|||
| 3741-PB | Microbial Burden, Species Signatures, and Major Thrombosis in Surgical Intensive Care Unit (SICU) Patients | Ioannis Karikis | Received |
|
|||
| 3751-PB | Heme-driven dysregulation of blood coagulation: Molecular insights into the modulation of blood coagulation factors and inhibitors by heme | Marie-T. Hopp | Received |
|
|||
| 3762-PB | Efficacy of L-arginine for reducing opioid use in pediatric patients hospitalized with sickle cell vaso-occlusive pain: A systematic review and meta-analysis | Felipe Michalczuk Barzon | Received |
|
|||
| 3771-PB | Socioeconomic status and mortality following a pulmonary embolism – a nationwide register-based study from Sweden. | Katarina Glise Sandblad | Received |
|
|||
| 3777-PB | Impact of Medical Inpatients Thrombosis and Hemostasis (MITH) Model Implementation on Venous Thromboembolism Pharmacophrophylaxis Rates and Clinical Outcomes | Allen Repp | Received |
|
|||
| 3778-PB | Impact of Early versus Delayed Thromboprophylaxis After Hip Fracture Surgery: A Retrospective Cohort Study Using Competing Risk Analysis | Fernando Jabif | Received |
|
|||
| 3780-PB | Federated Learning-Based Natural Language Processing for the Detection of Pulmonary Embolism in Electronic Health Records | Kayan Irani | Received |
|
|||
| 3782-PB | When in doubt suck it out? A retrospective cohort study of mechanical thrombectomy in intermediate-risk acute pulmonary embolism | Jacob Schmelz | Received |
|
|||
| 3783-PB | Real World Outcomes in Incidentally Diagnosed Isolated Subsegmental Pulmonary Embolism: Insights from the RIETE Registry | Liat Waldman Radinsky | Received |
|
|||
| 3784-PB | Early platelet flux is associated with severity of acute pulmonary embolism | Emily Mosher | Received |
|
|||
| 3786-PB | Hypoxia and right ventricular dysfunction in patients with acute pulmonary embolism | Karsten Stannek | Received |
|
|||
| 3788-PB | Venous Thromboembolism in Pregnancy and the Postpartum Period: A Multicenter Retrospective Cohort Study of Clinical Outcomes and Management Strategies | Isabelle MAHE | Received |
|
|||
| 3789-PB | Concordance of VTE Prophylaxis Practices With Risk Assessment Model Recommendations in Medical Inpatients | Katherine Fuller | Received |
|
|||
| 3793-PB | Hospital Volume, Care Pathways, and Mortality after Acute Pulmonary Embolism in France: A Nationwide Cohort Study, 2011–2024 | Ilham BENZIDIA | Received |
|
|||
| 3797-PB | Safety and efficiency of Adjust-Unlikely pulmonary embolism testing in the emergency department | Leela Breton | Received |
|
|||
| 3800-PB | Multimodal deep learning for pulmonary embolism screening using chest X-ray and electrocardiogram data | Barbara Lam | Received |
|
|||
| 3804-PB | Risky business: A retrospective cohort study of mechanical thrombectomy in high-risk acute pulmonary embolism | Jacob Schmelz | Received |
|
|||
| 3811-PB | Possible diagnostic value of the quotient of D-dimer and fibrinogen in pulmonary embolism and sepsis | Anita Kuruczné Kern | Received |
|
|||
| 3812-PB | Real-world Pulmonary Embolism Outcomes Following Large-Bore Mechanical Thrombectomy or Anticoagulation Alone from the Premier Healthcare Database | Jarrod Collins | Received |
|
|||
| 3814-PB | Bleeding Risk in venous thromboembolism patients: Impact of Selective Serotonin Reuptake Inhibitor use during Direct Oral Anticoagulant therapy - a nationwide observational register-based study | Maria Roupe | Received |
|
|||
| 3822-PB | Thrombotic Risk After Treatment Escalation to Janus Kinase Inhibitors in Rheumatoid Arthritis | Stephanie Tate | Received |
|
|||
| 3823-PB | Validation of CT Pulmonary Angiography Measurements in Patients with Pulmonary Embolism in the RIETE Registry | Parham Sadeghipour | Received |
|
|||
| 3826-PB | Evaluation of pulmonary embolism (PE) outcomes in a thrombosis multidisciplinary team (MDT) virtual model in a UK Acute Hospital | Natasha Wiles | Received |
|
|||
| 3833-PB | Optimizing Care Pathways for Troponin-Positive Pulmonary Embolism: Retrospective Baseline Metrics to Inform Prospective Quality-Improvement | Tegvir Grewal | Received |
|
|||
| 3837-PB | Allelic Expression of Factor V Leiden Mutation and Risk of Thrombosis | Eman Abdelghani | Received |
|
|||
| 3846-PB | Risk profile of antiphospholipid syndrome in patients with single LA-sensitive activated partial thromboplastin time (aPTT-LA) positivity. | Júlia Mellis | Received |
|
|||
| 3848-PB | Outcomes of Initial Anticoagulation at Hospital Discharge in Patients with Venous Thromboembolism and Subsequently Identified Antiphospholipid Antibodies | Idan Goldberg | Received |
|
|||
| 3852-PB | The Damage Index for Antiphospholipid Syndrome (DIAPS): Insights from the APS-Rio prospective cohort comparing DIAPS version 1 (DIAPSv1) versus DIAPS version 2 (DIAPSv2) | Gustavo Balbi | Received |
|
|||
| 3861-PB | REDUCED THROMBOMODULIN-MEDIATED THROMBIN GENERATION INHIBITION MIGHT BE A NEW THROMBOPHILIC BIOMARKER | Carlos Aguilar | Received |
|
|||
| 3866-PB | Use of direct anticoagulants in patients with antiphospholipid syndrome at the CHUS between 2010 and 2021 — A retrospective study of the quality of medical care | Dominique Toupin | Received |
|
|||
| 3867-PB | Is Elevated Factor VIII Associated With False-Negative Lupus Anticoagulant Testing? | Jacqueline Poston | Received |
|
|||
| 3874-PB | Comprehensive Characterization of Indeterminate/Discordant Lupus Anticoagulant Testing: A Tertiary-Center Experience | Rita Moukarzel | Received |
|
|||
| 3881-PB | Identification of Lupus Anticoagulant following an unexpected prolongation of prothrombin time: a reagent-dependant diagnostic pitfall | Mirvate HARB | Received |
|
|||
ISTH 2026 Congress
11 - 15 July Paris
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 11/07/2026 TO 11/07/2026
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
